A retrospective analysis of preemptive pharmacogenomic testing in 22,918 individuals from China
Quanfei Huang,Yuwei Liao,Tao Yu,Wei Lei,Hongfeng Liang,Jianxin Wen,Qing Liu,Yu Chen,Kaisheng Huang,Lifang Jing,Xiaoyan Huang,Yuanru Liu,Xiaokang Yu,Kaichan Su,Tengfei Liu,Liye Yang,Min Huang
DOI: https://doi.org/10.1002/jcla.24855
IF: 3.124
2023-03-16
Journal of Clinical Laboratory Analysis
Abstract:Distribution of number of genes with actionable genotypes and number of drugs with atypical therapeutic recommendations. Background Pharmacogenomics (PGx) examines the influence of genetic variation on drug responses. With more and more Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines published, PGx is gradually shifting from the reactive testing of single gene toward the preemptive testing of multiple genes. But the profile of PGx genes, especially for the intra‐country diversity, is not well understood in China. Methods We retrospectively collected preemptive PGx testing data of 22,918 participants from 20 provinces of China, analyzed frequencies of alleles, genotypes and phenotypes of pharmacogenes, predicted drug responses for each participant, and performed comparisons between different provinces. Results and Conclusion After analyzing 15 pharmacogenes from CPIC guidelines of 31 drugs, we found that 99.97% of individuals may have an atypical response to at least one drug; the participants carry actionable genotypes leading to atypical dosage recommendation for a median of eight drugs. Over 99% of the participants were recommended a decreased warfarin dose based on genetic factors. There were 20 drugs with high‐risk ratios from 0.18% to 58.25%, in which clopidogrel showed the highest high‐risk ratio. In addition, the high‐risk ratio of rasburicase in GUANGDONG (risk ratio (RR) = 13.17, 95%CI:4.06–33.22, p
medical laboratory technology